Clinical Data of First-in-class HBV-specificTCR T Cell Therapy (SCG101 …
Jun 7, 2024 · SCG101, an autologous T-cell receptor (TCR) T cell therapy, is an investigational cell therapy product targeting a specific epitope of hepatitis B surface antigen (HBsAg).
Clinical Data of First-in class HBV-specifcTCRT Cell Therapy (SCG101 ...
Jun 7, 2024 · SCG101, an autologous T-cell receptor (TCR) T cell therapy, is an investigational cell therapy product targeting a specific epitope of hepatitis B surface antigen (HBsAg). Utilizing SCG’s proprietary GianT TM technology , high affinity and high avidity natural TCR s can be identified against intracellular antigens present ed through m ajor ...
EASL Wrap-up Session Highlighted Late-Breaking Clinical Data
Jun 7, 2024 · SCG101, an autologous T-cell receptor (TCR) T cell therapy, is an investigational cell therapy product targeting a specific epitope of hepatitis B surface antigen (HBsAg).
691 First-in-human trial of novel HBsAg-specific TCR T cell therapy ...
SCG101, a first-in-class autologous HBsAg-specific TCR-T cell therapy, has demonstrated high affinity, avidity, and profound antiviral and antitumor functionalities in preclinical studies. This abstract presents the evaluation of SCG101 in subjects with …
Genetically-modified, redirected T cells target hepatitis B surface ...
May 29, 2024 · SCG101 is an autologous, HBV-specific T-cell product expressing a T-cell receptor (TCR) after lentiviral transduction recognizing the envelope-derived peptide (S20-28) on HLA-A2. We here validated its safety and efficacy preclinically and applied it to an HBV-related HCC patient (NCT05339321).
EASL Wrap-up: Late-Breaking Data on SCG101 TCR T Cell Therapy …
Jun 13, 2024 · SCG101, an investigational TCR T cell therapy, targets a specific epitope of the hepatitis B surface antigen (HBsAg). Utilizing SCG's proprietary GianTTM technology, the therapy identifies high-affinity TCRs against intracellular antigens presented by major histocompatibility complex (MHC) in solid tumors .
SCG Cell Therapy Announces U.S FDA Clearance of Investigational …
Jul 11, 2022 · SCG101 is an autologous TCR T cell therapy that can recognize HBV-derived T cell epitope presented on the cell surface by specific major histocompatibility complex (MHC) class I molecules.
EASL Wrap-up Session Highlighted Late-Breaking ... - Pipelinereview
Jun 7, 2024 · SCG101, an autologous T-cell receptor (TCR) T cell therapy, is an investigational cell therapy product targeting a specific epitope of hepatitis B surface antigen (HBsAg).
SCG Cell Therapy Announces U.S FDA Clearance of ... - BioSpace
Jul 11, 2022 · Singapore-based SCG Cell Therapy Pte Ltd announced that U.S. Food and Drug Administration has cleared the Investigational New Drug application for SCG101, an investigational T-cell receptor T cell therapy for patients with hepatitis B virus related liver cancer.
EASL Wrap-up Session Highlighted Late-Breaking Clinical Data of …
Jun 7, 2024 · SCG101, an autologous T-cell receptor (TCR) T cell therapy, is an investigational cell therapy product targeting a specific epitope of hepatitis B surface antigen (HBsAg). Utilizing SCG's proprietary GianT TM technology, high affinity and high avidity natural TCRs can be identified against intracellular antigens presented through major ...
- Some results have been removed